NASDAQ:AKUSAkouos Stock Price, Forecast & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akouos in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Akouos.

5 analysts have issued 1 year price objectives for Akouos' stock. Their forecasts range from $24.00 to $40.00. On average, they expect Akouos' stock price to reach $30.75 in the next year. This suggests a possible upside of 45.4% from the stock's current price.
View analysts' price targets for Akouos.

Media headlines about AKUS stock have trended neutral on Wednesday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akouos earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Akouos.

Some companies that are related to Akouos include Insmed (INSM), Deciphera Pharmaceuticals (DCPH), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), SAGE Therapeutics (SAGE), Pacira Biosciences (PCRX), TG Therapeutics (TGTX), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), Prestige Consumer Healthcare (PBH), Ligand Pharmaceuticals (LGND), Uniqure (QURE), Aurinia Pharmaceuticals (AUPH) and Xencor (XNCR).
View all competitors.

(AKUS) raised $124 million in an initial public offering on Friday, June 26th 2020. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager.

Akouos trades on the NASDAQ under the ticker symbol "AKUS."

Akouos' quiet period expired on Wednesday, August 5th. Akouos had issued 12,500,000 shares in its initial public offering on June 26th. The total size of the offering was $212,500,000 based on an initial share price of $17.00. During Akouos' quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Shares of AKUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AKUS stock can currently be purchased for approximately $21.15.

Akouos has a market capitalization of $686.99 million.

The official website for Akouos is www.akouos.com.

Akouos' mailing address is 645 SUMMER STREET SUITE 200, BOSTON MA, 02210. The company can be reached via phone at 857-245-5715 or via email at [email protected]